Five Prime’s Phase 1 Trial Begins FPA150 Dosing Among Solid Tumor Patients
News
The Phase 1a/1b trial evaluating Five Prime Therapeutics‘ checkpoint inhibitor FPA150 in patients with advanced solid cancers has begun dosing patients ahead of schedule, the company announced. FPA150 is an antibody that targets ... Read more